Business / Finance

RSS

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Pivotal Therapeutics Inc., ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its accomplishments and financial results for the three months ended September 30, 2014.

29 Nov 2014

Roche Holdings declares final results of its previously announced tender offer

Roche Holdings, Inc. (the "Offeror") announced today the final results of its previously announced tender offer (the "Offer") to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2.2 billion (the "Maximum Tender Amount") the 5.25% Senior Notes due 2035 issued by the Offeror's subsidiary Genentech, Inc.

29 Nov 2014

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company that engages in the development and commercialization of targeted therapeutics for the treatment of inflammatory diseases and cancer, today completed the underwriter's exercise of partial over-allotment option of 459,697 units, at a price of $2.50 per unit, for gross proceeds of approximately $1.06 million, bringing the aggregate gross proceeds of the Company's previously announced underwritten public offering to $9.685 million.

27 Nov 2014

CARsgen announces completion of series A financing

CARsgen, a leader in the development of Chimeric Antigen Receptors T (CAR-T) cell immunotherapy to treat a variety of cancers, today announced the completion of a series A financing led by BVCF, a China-based healthcare private equity fund.

26 Nov 2014

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Promethera Biosciences, a Belgian biotechnology company developing Promethera HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces the completion of its Series C fundraising round. The company has raised €25.33 million ($31.4 million), including €20.33 million in capital.

26 Nov 2014

Nepstar revenue increases 8.1% to RMB738.3 million (US$120.3million) in Q3 2014

China Nepstar Chain Drugstore Ltd., a leading retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the third quarter ended September 30, 2014.

26 Nov 2014

Gamma Medica, Volpara Solutions partner to improve breast cancer screening

Gamma Medica, developer of advanced digital molecular imaging technologies for the detection of breast cancer, is pleased to announce a new strategic partnership with Volpara Solutions, leaders in the development of quantitative breast imaging tools. By using these technologies in parallel, physicians can implement screening protocols based on a woman’s breast density and individual risk factors.

25 Nov 2014

ProMedica invests in early stage medical device company

ProMedica has invested in an early stage medical device company that is developing and commercializing innovative and cost-effective devices for treating common vascular diseases such as peripheral artery disease (PAD). Jobst Vascular Surgeon John Pigott, MD, founded the Sylvania-based company, VentureMed Group, and its first invention is already being used in clinical trials underway in Europe.

25 Nov 2014

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Merck, known as MSD outside the United States and Canada, and NewLink Genetics Corporation, announced today that they have entered into an exclusive worldwide license agreement to research, develop, manufacture, and distribute NewLink's investigational rVSV-EBOV (Ebola) vaccine candidate.

24 Nov 2014

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Endo International plc, announced today the acquisition of rights to Natesto (testosterone nasal gel), the first and only testosterone nasal gel for replacement therapy in adult males diagnosed with hypogonadism, from Trimel BioPharma SRL, a wholly-owned subsidiary of Trimel Pharmaceuticals Corporation.

24 Nov 2014

Abaxis completes acquisition of QCR & Trio Diagnostics

Abaxis, Inc., a medical products company manufacturing point-of-care instruments and consumables for the medical, research, and veterinary markets worldwide and providing reference lab services to the veterinary and research markets in the United States, announced today the completion of a stock purchase agreement to acquire 100% of QCR & Trio Diagnostics Limited, a United Kingdom based distribution organization.

21 Nov 2014

Lexicon prices $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes

Lexicon Pharmaceuticals, Inc. today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes") in a private offering within the United States.

21 Nov 2014

Lexicon announces pricing of underwritten public offering of common stock

Lexicon Pharmaceuticals, Inc. today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement.

21 Nov 2014

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Aequus Pharmaceuticals Inc. (the "Company" or "Aequus") is pleased to announce that it has closed a brokered private placement offering (the "Brokered Offering") of special warrants for approximately C$3.7 million.

21 Nov 2014

Coqui Pharma signs contract with INVAP to design Medical Isotope Production Facility in Alachua, Fla

Coqui RadioPharmaceuticals Corp., a medical isotope company working to become the first U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to announce it has formally signed a contract with INVAP to design its Medical Isotope Production Facility (MIPF) in Alachua, Fla. Mo-99 is the parent isotope of Technetium-99, which is used in 80 percent of nuclear medicine procedures worldwide.

20 Nov 2014

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.

20 Nov 2014

Cyberonics' worldwide net sales increase 5% to $73.4M in Q2 of fiscal 2015

Cyberonics, Inc. today announced results for the quarter ended October 24, 2014.

20 Nov 2014

Echo Therapeutics reports net loss of $5.5 million for third quarter 2014

Echo Therapeutics, Inc., a medical device company, today announced its financial results for the quarter ended September 30, 2014.

19 Nov 2014

EvergreenHealth, Valley General Hospital approve final phase of alliance agreement

EvergreenHealth and Valley General Hospital announced today that their respective Boards of Commissioners have voted to approve the third and final phase of an alliance agreement in which Valley General Hospital in Monroe, Washington will become part of the Kirkland-based health care system and managed by EvergreenHealth.

19 Nov 2014

Moffitt announces development of innovative investigational biologic agent for MDS

In a major step to treat patients living with Myelodysplastic Syndromes (MDS), a group of diseases that affect the bone marrow and blood, Moffitt Cancer Center today announced the development of an innovative investigational biologic agent that could improve patient response and outcomes for MDS and other diseases.

18 Nov 2014

Business / Finance

Pivotal Therapeutics announces accomplishments, financial results for Q3 2014

Roche Holdings declares final results of its previously announced tender offer

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

CARsgen announces completion of series A financing

Promethera Biosciences completes €25.33 million ($31.4 million) Series C fundraising

Nepstar revenue increases 8.1% to RMB738.3 million (US$120.3million) in Q3 2014

Gamma Medica, Volpara Solutions partner to improve breast cancer screening

ProMedica invests in early stage medical device company

Merck, NewLink Genetics sign exclusive worldwide license agreement for Ebola vaccine candidate

Endo announces acquisition of rights to Natesto (testosterone nasal gel)

Abaxis completes acquisition of QCR & Trio Diagnostics

Lexicon prices $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes

Lexicon announces pricing of underwritten public offering of common stock

Aequus Pharmaceuticals closes $4.2M private placement offering of special warrants

Coqui Pharma signs contract with INVAP to design Medical Isotope Production Facility in Alachua, Fla

Apellis Pharmaceuticals signs agreement to acquire Potentia Pharmaceuticals

Cyberonics' worldwide net sales increase 5% to $73.4M in Q2 of fiscal 2015

Echo Therapeutics reports net loss of $5.5 million for third quarter 2014

EvergreenHealth, Valley General Hospital approve final phase of alliance agreement

Moffitt announces development of innovative investigational biologic agent for MDS

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Latest News